Complete objective response of oesophageal squamocellular carcinoma to biological treatment

Neuroendocrinology Letters

Volumn 30, Issue 3, 2009, Pages 312-321

  Di Bella, Giuseppe ^a   Madarena, Mauro ^a  

^a NONE

Author keywords

Biological treatment; Melatonin; Oesophageal carcinoma; Remission induction; Somatostatin

Indexed keywords

ADENOSINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BROMOCRIPTINE; CABERGOLINE; CALCIUM; CHONDROITIN SULFATE; COLECALCIFEROL; CYCLOPHOSPHAMIDE; DIHYDROTACHYSTEROL; ENALAPRIL; GLUCOSAMINE DERIVATIVE; GLUCOSAMINE SULFATE; GLYCERYL TRINITRATE; GLYCINE; LANSOPRAZOLE; LEVOTHYROXINE; MELATONIN; METOCLOPRAMIDE; OCTREOTIDE; PALMITATE AXEROPHTHOL; PHENOBARBITAL; RETINOIC ACID; RETINOID DERIVATIVE; SOMATOSTATIN; UNCLASSIFIED DRUG;

AGED; APOPTOSIS; ARTICLE; BIOLOGICAL THERAPY; CANCER GRADING; CANCER STAGING; CASE REPORT; CONVALESCENCE; DRUG EFFICACY; EPILEPSY; ESOPHAGUS CARCINOMA; EVENING DOSAGE; FUNCTIONAL STATUS; HOMEOSTASIS; HOSPITALIZATION; HUMAN; HYPERTENSION; INOPERABLE CANCER; LUNG CARCINOMA; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 70450285293     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Albini A, Florio T, Giunciuglio D, et al. (1999). Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J. 13(6): 647-655. (Pubitemid 29156396)
2. Ashino H, Shimamura M, Nakajima H, et al. (2003). Novel function of ascorbic acid as an angiostatic factor. Angiogenesis. 6(4): 259-269. (Pubitemid 38987535)
3. Barnett P (2003). Somatostatin and somatostatin receptor physiology. Endocrine. 20(3): 255-264.
4. Barrie R, Woltering EA, Hajarizadeh H (1993). Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res. 55(4): 446-450. (Pubitemid 23346888)
5. Barroga EF, Kadosawa T, Okumura M (2000). Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. Res Vet Sci. 68(1): 79-87. (Pubitemid 30107755)
6. Batra RK, Olsen JC, Hoganson DK (1997). Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem. 272(18): 11736-11743
7. Ben-Jonathan N, Liby K, McFarland M (2002). Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab. 13(6):245-250. (Pubitemid 36733969)
8. Cameron E, Pauling L, Leibovitz B (1979). Ascorbic acid and cancer: a review. Cancer Res. 39(3): 663-681.
9. Cascinu S, Del Ferro E, Ligi M, Staccioli, et al. (2001). Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest. 19(1): 8-12. (Pubitemid 32233796)
10. De Souza I, Morgan L, Lewis UL (1974). Growth-hormone dependence among human breast cancers. Lancet. 2(7874):182-184.
11. Di Bella L, Gualano L (2006). Key aspects of melatonin physiology: thirty years of research. Neuro Endocrinol Lett. 27(4): 425-432. (Pubitemid 46043597)
12. Di Bella L, Rossi MT, Scalera G (1979). Perspectives in pineal functions. Prog Brain Res. 52: 475-478.
13. Dong LM, Kristal AR, Peters U (2008). Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.Nutr Cancer. Jan-Feb; 60(1):39-48
14. Florio T, Morini M, Villa V, et al. (2003). Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 144(4): 1574-1584. (Pubitemid 36428500)
15. Giovannucci E, Liu Y, Willett WC (2006). Cancer incidence and mortality and vitamin D in black and white male health professionals.Cancer Epidemiol Biomarkers Prev. Dec; 15(12): 2467-2472 Epub Nov 28.
16. Griffin M, Sweeney EC (1987). The relationship of endocrine cells, dysplasia and carcinoembryonic antigen in Barrett's mucosa to adenocarcinoma of the oesophagus.Histopathology. Jan; 11(1): 53-62.
17. Gruszka A, Pawlikowski M, Kunert-Radek J (2001). Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. Neuro Endocrinol Lett. 22(5): 343-348. (Pubitemid 33036843)
18. Hashimoto Y, Shimada Y, Itami A (2003). Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma.Eur J Cancer. Oct; 39(15): 2239-2246
19. Head KA (1998). Ascorbic acid in the prevention and treatment of cancer. Altern Med Rev. 3(3): 174-186. (Pubitemid 128709127)
20. Held-Feindt J, Krisch B, Mentlein R (1999). Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells. Brain Res Mol Brain Res. 64(1): 101-107
21. Hooghe R, Merchav S, Gaidano G (1998). A role for growth hormone and prolactin in leukaemia and lymphoma? Cell Mol Life Sci. 54(10): 1095-1101.
22. Israel K, Yu W, Sanders BG, Kline K (2000). Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer. 36(1): 90-100. (Pubitemid 30317840)
23. Jatoi A & Thomas CR Jr (2002). Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Semin Radiat Oncol. Jan; 12(1 Suppl 1): 62-67 (Pubitemid 34246071)
24. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001). Inhibitory effects of 1 alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 15(8): 1370-1380.
25. Jia WD, Xu GL, Xu RN, et al. (2003). Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol. 129(6): 327-334.
26. Jin Z, Mori Y, Hamilton JP (2008). Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. Jan 1; 112(1): 43-49
27. Kapil U, Srivastav M, Nayar D (1993). Vitamin 'A' and oesophageal cancer. Trop Gastroenterol. Jul-Sep; 14(3): 87-90.
28. Kath R & Höffken K (2000). The significance of somatostatin analogues in the antiproliferative treatment of carcinomas. Recent Results Cancer Res. 153: 23-43.
29. Khuri FR, Kim ES, Lee JJ (2001). The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2001 Aug; 10(8): 823-829
30. Kidd PM (2000).The use of mushroom glucans and proteoglycans in cancer treatment.Altern Med Rev. Feb; 5(1): 4-27. Review.
31. Kini AR, Peterson LA, Tallman MS, Lingen MW (2001). Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 97(12): 3919-3924.
32. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, et al. (2003). Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. 5(1): 32-40. (Pubitemid 36151056)
33. Kvetnoy IM & Levin IM (1986). Melatonin and tumor growth.(In Russian with English abstract). Eksp Onkol. 8(4): 11-15.
34. Launoy G, Milan C, Day NE, Pienkowski MP (1998). Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study.Int J Cancer. Mar 30; 76(1): 7-12.
35. Lincoln DT, Sinowatz F, Temmim-Baker L, et al. (1998). Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells. Histochem Cell Biol.; 109(2): 141-159. (Pubitemid 28085687)
36. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ (2001). Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 22(1): 45-47. (Pubitemid 32186250)
37. Liu G, Wu M, Levi G (1998). Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int J Cancer. Oct 5; 78(2): 248-254 (Pubitemid 28443184)
38. Liu Y, Yang H, Otaka K, Takatsuki H, Sakanishi A (2005). Effects of vascular endothelial growth factor (VEGF) and chondroitin sulfate A on human monocytic THP-1 cell migration. Colloids Surf B Biointerfaces. 43(3-4): 216-220. (Pubitemid 40909845)
39. Lotan R (1997). Retinoids and chemoprevention of aerodigestive tract cancers Cancer Metastasis Rev. Sep-Dec; 16(3-4): 349-356
40. Lubin JH, Virtamo J, Weinstein SJ (2008). Cigarette smoking and cancer: intensity patterns in the alpha-tocopherol, beta-carotene cancer prevention study in Finnish men.Am J Epidemiol. Apr 15; 167(8): 970-975 Epub 2008 Feb 3.
41. Maestroni GJ, Hertens E, Galli P, Conti A, Pedrinis E (1996). Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin. J Pineal Res. 21(3): 131-139 (Pubitemid 126733145)
42. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W (1994). Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer. 57(1): 81-85. (Pubitemid 24117104)
43. Malafa MP, Fokum FD, Smith L, Louis A (2002). Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Ann Surg Oncol. 9(10): 1023-1032. (Pubitemid 35424639)
44. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000). 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 87(3): 214-220.
45. McMillan K, Perepelitsyn I, Wang Z, Shapshay SM (1999). Tumor growth inhibition and regression induced by photothermal vascular targeting and angiogenesis inhibitor retinoic acid. Cancer Lett. 137(1): 35-44. (Pubitemid 29179494)
46. Meggouh F, Lointier P, Pezet D (1990). Evidence of 1,25-dihydroxyvitamin D3-receptors in human digestive mucosa and carcinoma tissue biopsies taken at different levels of the digestive tract, in 152 patients.J Steroid Biochem. Jun; 36 (1-2): 143-147 (Pubitemid 20213578)
47. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J (2001). Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer.; 92(4): 545-550. (Pubitemid 32319428)
48. Mikami S, Ohashi K, Usui Y, NemotoT, Katsube K, Yanagishita M, Nakajima M, Nakamura K, Koike M (2001). Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas Jpn J Cancer Res. Oct; 92(10): 1062-1073
49. Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, et al. (1999). Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. Am J Obstet Gynecol. 181(3): 583-590.
50. Muller A, Nakagawa H, Rustgi AK (1997). Retinoic acid and N-(4-hydroxy-phenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Cancer Lett. Feb 26; 113(1-2): 95-101.
51. Murata A, Morishige F, Yamaguchi H (1982). Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl.; 23: 103-113.
52. Neuzil J, Kagedal K, Andera L, Weber C, Brunk UT (2002). Vitamin E analogs: a new class of multiple action agents with antineoplastic and anti-atherogenic activity. Apoptosis. 7(2): 179-187 (Pubitemid 34273134)
53. Norsa A. and Martino V (2007). Somatostatin, Retinoidi, Melatonin, Vitamin D, Bromocriptine, and Cyclophosphamide in Chemotherapy-Pretreated Patients with Advanced Lung Adenocarcinoma and Low Performance Status. Cancer Biotherapy & Radiopharmaceuticals. 22 (1): 50-55
54. Odeleye OE, Eskelson CD, Mufti SI, Watson RR (1992a). Vitamin E inhibition of lipid peroxidation and ethanol-mediated promotion of esophageal tumorigenesis. Nutr Cancer. 17(3): 223-234
55. Odeleye OE, Eskelson CD, Mufti SI, Watson RR (1992). Vitamin E protection against nitrosamine-induced esophageal tumor incidence in mice immunocompromised by retroviral infection. Carcinogenesis. Oct; 13(10): 1811-1816
56. Onogi N, Okuno M, Matsushima-Nishiwaki R, Fukutomi Y, Moriwaki H, Muto Y, et al. (1998). Antiproliferative effect of carotenoids on human colon cancer cells without conversion to retinoic acid. Nutr Cancer. 32(1): 20-24.
57. Ozerdem U, Stallcup WB (2004). Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis. 7(3): 269-276.
58. Piedrafita FJ & Pfahl M (1997). Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol. 17(11): 6348-6358
59. Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD (2002). Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res. 62(13): 3722-3728 (Pubitemid 34728853)
60. Roth AD, Morant R, Alberto P (1999). High dose etretinate and interferon-alpha - a phase I study in squamous cell carcinomas and transitional cell carcinomas. Acta Oncol. 38(5): 613-617 (Pubitemid 29333742)
61. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. (2001). Hypothalamic hormones and cancer. Front Neuroendocrinol. 22(4): 248-291.
62. Shimizu M, Suzui M, Deguchi A (2004). Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res. Feb 1; 10(3): 1130-1140 (Pubitemid 38198915)
63. Shklar G & Schwartz JL (1996). Vitamin E inhibits experimental carcinogenesis and tumour angiogenesis. Eur J Cancer B Oral Oncol. 32B(2): 114-119. (Pubitemid 26153214)
64. Szepesházi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, et al. (1999). Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with. J Cancer Res Clin Oncol. Aug-Sep; 125(8-9): 444-452 (Pubitemid 29410408)
65. Tang FY & Meydani M (2001). Green tea catechins and vitamin E inhibit angiogenesis of human microvascular endothelial cells through suppression of IL-8 production. Nutr Cancer. 41(1-2): 119-125.
66. Todisco M, Casaccia P, Rossi N (2001). Cyclophosphamide plus somatostatine, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade none-Hodgkin's lymphomas at advanced stage: results of a phase II trial. Cancer Biother Radiopharm. 16(2):171-177 (Pubitemid 34121641)
67. Turley JM, Funakoshi S, Ruscetti FW, Kasper J, Murphy WJ, Longo DL, et al. (1995). Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor beta. Cell Growth Differ. 6(6): 655-663.
68. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000). Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinol. 165(2): 475-481. (Pubitemid 30341096)
69. Vidal S, Oliveira MC, Kovacs K, Scheithauer BW, Lloyd R (2000). Immunolocalization of vascular endothelial growth factor in the GH3 cell line. Cell Tissue Res. 300(1): 83-88. (Pubitemid 30209766)
70. Wang C, Tammi M, Guo H, Tammi R, Hyaluronan (1996). Distribution in the normal epithelium of esophagus, stomach, and colon and their cancers.Am J Pathol. Jun; 148(6): 1861-1869
71. Wang ZH, Yam HF, Or PC, Yang L (1999). Effects of all-trans-retinoic acid on human esophageal carcinoma cells and their nuclear matrices. Anticancer Res. Jan-Feb; 19(1A): 563-568
72. Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, et al. (2001). Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 85(2): 266-272. (Pubitemid 32695750)
73. Wiedermann CJ, Reinisch N, Braunsteiner H (1993). Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood. 82(3): 954-960. (Pubitemid 23221681)